Related Experiment Video
Updated: Aug 18, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Survival rate of 2636 patients with bronchogenic carcinoma]
1Shanghai Chest Hospital.
Abstract:
2636 patients with bronchogenic carcinoma treated by resection are analyzed. The 5- and 10-year survival rates were 40.6% and 29.8%, respectively. The main factors influencing the survival rates are: 1. Pathology stage: The 5-year survival rates of stages I, II, and III were 58.3%, 33.6% and 26.4% and 10-year survival rates were 44.6%, 23.8% and 17.8%, respectively while in stage III, the 5-year survival rate of T3N0M0 was much better than that of N2 group, 43.2% and 16.7%; 2. Histology type: Squamous type had the best 5-year survival rate (47.9%) and adenocarcinoma worse (35.7%). Though the 5-year survival rate of small cell lung cancer was the lowest (21.2%), it was twice as high as the group treated by surgery only which was reported in 1979. We consider that it is due to the beneficial effect of chemotherapy instituted with surgery since 1976 3. The prognosis of specimens with negative stump was better than those with positive ones. There are no obvious differences in the prognosis affected by other factors such as age, sex, smoking history, time of diagnosis, central or peripheral type, preoperative radiotherapy or the extent of surgery.

